Company / Shareholders' Equity
Charles River Laboratories Shareholders' Equity History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$3.2B
FY2025
5-year range
$2.5B / $3.6B
FY2021-FY2025
Trend
-8.6%
vs FY2024
Sector context
#39 of 160
Health Care
What the data says
Charles River Laboratories's shareholders' equity of $3.2B is higher than 76% of companies in the Health Care sector (FY2025). Declined from $3.6B to $3.2B over the past 2 years.
Based on SEC 10-K filings.
$3.2B in FY2025 with a 5-year CAGR of +8.4%. Top quartile in the Health Care sector.
Declined from $3.6B to $3.2B over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- +2.1%
- 5-Year CAGR
- +8.4%
- 10-Year CAGR
- -
Sector benchmark
Top 24% in Health CareTop 24% of 160This company $3.2B Sector average $5.0B
▼
-37.3% below sector average
Key checks
Key Insights
- 5-year CAGR of +8.4%, indicating consistent growth.
- In FY2025, shareholders' equity decreased 8.6% year-over-year.
- Ranks #39 out of 160 companies in the Health Care sector.
- Peak shareholders' equity was recorded in FY2023.
Company context
Key Data Points
- Altman Z-Score 1.10 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $3.2B | -8.6% |
| FY2024 | $3.5B | -3.8% |
| FY2023 | $3.6B | +20.9% |
| FY2022 | $3.0B | +17.4% |
| FY2021 | $2.5B | +19.9% |
| FY2020 | $2.1B | +29.4% |
| FY2019 | $1.6B | +24.1% |
| FY2018 | $1.3B | +26.1% |
| FY2017 | $1.0B | +24.9% |
| FY2016 | $836.8M | +14.1% |
As of FY2025 · SEC 10-K · Updated Jul 4, 2026